Leadership Overview
Renata Limited has 4 executives leading key functions including corporate strategy, operational management, financial oversight, and human capital development.
Committed to advancing global health standards, Renata Limited delivers high-quality pharmaceutical and animal health solutions while maintaining a rigorous focus on innovation and sustainable manufacturing practices across diverse medical sectors.
Committed to advancing global health standards, Renata Limited delivers high-quality pharmaceutical and animal health solutions while maintaining a rigorous focus on innovation and sustainable manufacturing practices across diverse medical sectors.
Leadership Roles at Renata Limited
Kaiser Kabir - Chief Executive Officer
Kaiser Kabir, the Chief Executive Officer at Renata Limited, directs the overarching strategic vision for the pharmaceutical and animal health manufacturing divisions. Kabir architects long-term growth initiatives, focusing on the expansion of synthetic hormone production and oncological drug portfolios. By aligning research and development priorities with emerging market needs, the Chief Executive Officer ensures the company maintains a competitive edge in the regional healthcare landscape. This leadership role involves constant collaboration with the Board to optimize manufacturing efficiency and product quality standards. Kaiser Kabir monitors global industry trends to identify new opportunities for therapeutic advancement. Through the implementation of robust operational frameworks, the Chief Executive Officer drives organizational excellence and ensures that all business units adhere to strict regulatory compliance. Ultimately, Kabir secures the company's position as a leader in the pharmaceutical sector by fostering a culture of continuous improvement and scientific innovation.
Syed Kabir - Chief Executive Officer and Managing Director, Renata PLC
Syed Kabir, the Chief Executive Officer and Managing Director, Renata PLC at Renata Limited, manages the daily operational execution and corporate governance of the organization. Syed Kabir oversees the integration of animal health and nutrition product lines into the broader corporate strategy, ensuring consistent revenue growth across all business segments. The Chief Executive Officer and Managing Director, Renata PLC coordinates with internal departments to streamline supply chain logistics and enhance distribution networks throughout the region. This role requires balancing immediate production demands with the long-term objective of scaling manufacturing capacity for contraceptives and other essential medications. By maintaining strong relationships with stakeholders and regulatory bodies, the Chief Executive Officer and Managing Director, Renata PLC guarantees operational stability. Through rigorous oversight of resource allocation, Kabir optimizes the company's internal processes, ensuring that every manufacturing facility operates at peak performance to meet the evolving needs of the healthcare market.
Mustafa Aolad - Chief Financial Officer
Mustafa Aolad, the Chief Financial Officer at Renata Limited, directs the financial planning, risk management, and capital allocation strategies for the entire organization. Aolad architects fiscal policies that support the manufacturing of complex pharmaceutical products, including synthetic hormones and oncological drugs. By analyzing market data and operational costs, the Chief Financial Officer ensures the company maintains a healthy balance sheet while funding critical research and development projects. This leadership role involves providing the Board with accurate financial forecasting to guide investment decisions in new technology and infrastructure. Mustafa Aolad monitors cash flow and liquidity to mitigate risks associated with international supply chains and raw material procurement. Through the implementation of stringent financial controls, the Chief Financial Officer drives profitability and long-term value creation. Ultimately, Aolad secures the financial foundation necessary for the company to continue delivering high-quality health solutions to diverse patient populations.
Nisbat Anwar - Chief People Officer
Nisbat Anwar, the Chief People Officer at Renata Limited, directs the human capital strategy, talent acquisition, and organizational development initiatives. Anwar architects programs that foster a high-performance culture within the pharmaceutical and animal health manufacturing teams. By aligning workforce capabilities with the company's technical requirements, the Chief People Officer ensures that the organization attracts and retains top-tier scientific and operational talent. This leadership role involves designing comprehensive training frameworks that emphasize safety, quality control, and innovation in drug production. Nisbat Anwar manages employee engagement and performance management systems to support the company's growth objectives across all regional operations. Through the development of inclusive workplace policies, the Chief People Officer drives organizational cohesion and operational efficiency. Ultimately, Anwar secures the human resources necessary to maintain the company's reputation for excellence in the pharmaceutical industry, ensuring that every team member contributes effectively to the broader mission.
Explore Leadership Teams in Manufacturing
Cipla Limited is a global pharmaceutical company based in Mumbai, India, with operations in India, the United States, South Africa, and other international markets. Through its Pharmaceuticals and New Ventures segments, the company develops, manufactures, markets, and distributes a broad range of generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and finished formulations. Its products address multiple therapeutic areas, including cardiovascular disease, pulmonary and kidney conditions, neurological and psychiatric disorders, HIV/AIDS, respiratory and asthma care, oncology, diabetes and metabolic disorders, infectious diseases, critical care, women’s health, ophthalmology, and child health. In addition to its core pharmaceutical portfolio, Cipla is active in consumer healthcare, biosimilars, and specialty medicine businesses. Founded in 1935, Cipla has grown into a major global healthcare player.
Company Leadership MF
PJ
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is headquartered in South Plainfield, New Jersey.
Company Leadership LB
DM

Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Founded in 1988 and headquartered in Westbury, New York, PL Developments is a manufacturer, packager, and distributor of pharmaceutical and consumer healthcare products.
Company Leadership CC
AS
CN
AN